Evaluation of the CUP clinical care pathway

Status: Ongoing.

A major step forward is the introduction of Whole Genome Sequencing (WGS) in the Cancer of Unknown Primary Tumor (CUP) care pathway in the Netherlands in 2022. This technique can be used to determine the suspected tissue of origin in many CUP patients. As a result, a diagnosis other than CUP can be made in a significant number of patients; for example, breast or lung cancer. This can then be used to provide targeted treatment with the aim of improving survival. The implementation of WGS in the CUP care pathway is unique in the world and therefore also offers an exceptional opportunity to see what WGS generally yields. Additional information will be collected for this purpose in the coming year from CUP patients who have had WGS. This is to evaluate for how many patients it ultimately led to the rejection of the CUP diagnosis, how many patients were found to have drugable targets, but also in what percentage of patients WGS led to a change in treatment and whether it led to treatment in a study context.